Australian biotech market today 14.04.09
Tuesday, 14 April, 2009
The overall healthcare index was up on today’s trading at 2.30pm, following the trend of the rest of the indices. The All Ordinaries is up 2.5 per cent.
Cellestis (ASX:CST) is up 19c to $2.55 on the news that its TB diagnostic QuantiFERON-TB Gold In-Tube has received regulatory approval in Japan.
ChemGenex (ASX:CXS) is continuing to enjoy gains after announcing it had raised $10 million in secondary financing last week, up 4c to 46c.
Acrux (ASX:ACR) is up 2c to 65c, as is Biota (ASX:BTA) to 66c. Mesoblast (ASX:MSB) is up 5c to 85c.
Cochlear (ASX:COH) is up 68c, CSL (ASX:CSL) is down 11c and ResMed (ASX:RMD) is up 4c.
Pharmaxis (ASX:PXS) is down a steep 13c to $2.02 on reasonable volumes, as is Novogen (ASX:NRT), down 13.5 per cent to 48c. QRxPharma (ASX:QRX) is up 4c to 32c.
Progen (ASX:PGL) is up 3.8 per cent to 95c while Probiotec (ASX:PBP) is again enjoying healthy rises, up 6.2 per cent to $1.89.
Living Cell Technologies (ASX:LCT) is down 3.5c to 12c, while there has been some rare movement with LabTech Systems (ASX:LBT), up a cent to 14.5.
Scientists optimise delivery of mRNA to target cells
A highly versatile new method captures and attaches antibodies to the surface of mRNA-loaded...
'Anti-reward' brain network helps explain cocaine addiction
A new study identifies a specific 'anti-reward' network deep in the brain that undergoes...
Intense grief linked to higher risk of death for a decade
Researchers have found that bereaved people with persistent high levels of intense grief use more...
